Content area
Abstract
4 AZA Bioscience, Acologix, Inc., Adnavance Technologies, Inc., AerovectRx Corporation, Alder Biopharmaceuticals, Antibe Therapeutics Inc.,AquaGenvx Pharmaceuticals, Cardiome Pharma Corp., EcoBiotics, Evolva AG, iCo Therapeutics Inc., KAI Pharmaceuticals, Nerites Corporation, Nura Inc., PainCeptor Pharma, Predix Pharmaceuticals, Reata Pharmaceuticals, Inc., Replikun Biotech Pty Limited, Talisker Pharma Ltd., and Vitae Pharmaceuticals, Inc.
Alchemia Limited, Allon Therapeutics Inc., Alphora Research Inc., Antisoma, Atugen AG, Avidex Ltd., Biolex Theraputics, BioWa, Inc., Boston Life Sciences, Inc., CANTEST BioPharma Services, Celator Pharmaceuticals, Cell Signals Inc., Corgentech, Curis, Inc., Engene Inc., Evolutec Group Plc, Forbes Medi-Tech Inc., ImaRx Therapeutics, Inc., Ingenium Pharmaceuticals, Inimex Pharmaceuticals, Inc., InNexus Biotech, Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Liponex Inc., MaxCyte, Inc., Medicago Inc., Meristem Therapeutics, Miltenyi Bioprocess, Novacta Biosystems Ltd., NovaDel Pharma, Novozymes A/S, Nycomed, Oncolytics Biotech Inc., Oxford BioMedica, Paradigm Therapeutics Ltd., Patheon Inc., Pharmacyclics, Product Safety Labs, Protox Therapeutics, PTC Therapeutics, Inc., QSV Biologics Limited, Santaris Pharma, SemBioSys Genetics, Stem Cell Therapeutics Corp., TopoTarget UK Ltd., Torcan Chemical Ltd., ToxTest, Transition Therapeutics Inc., Trigen Holdings AG, Trophos, Urigen, Xantos Biomedicine AG, XOMA Ltd., and YM BioSciences Inc.